The invention is concerned with the compounds of formula I or II: ##STR00001##
and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Sulfur chelated ruthenium compounds represented by the following formula: ##STR00001##
wherein M indicates the ruthenium metal bound to a benzylidene carbon; R represents C.sub.1-C.sub.7 alkyl group or optionally substituted aryl; X.sub.1 and X.sub.2 each independently represent halogen; Y.sub.1 and Y.sub.2 each independently denote unsubstituted or alkyl-substituted phenyl; and Z independently represents hydrogen, electron withdrawing or electron donating substituent, with m being an integer from 1 to 4, and processes and compositions related thereto.

Sulfur chelated ruthenium compounds represented by the following formula: ##STR00001##
wherein M indicates the ruthenium metal bound to a benzylidene carbon; R represents C.sub.1-C.sub.7 alkyl group or optionally substituted aryl; X.sub.1 and X.sub.2 each independently represent halogen; Y.sub.1 and Y.sub.2 each independently denote unsubstituted or alkyl-substituted phenyl; and Z independently represents hydrogen, electron withdrawing or electron donating substituent, with m being an integer from 1 to 4, and processes and compositions related thereto.

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

Novel substituted 5 membered heterocyclic compounds of Formula I are disclosed. The invention further discloses a process for the preparation of compounds of Formula I. The compounds find use as anti mycobacterial agents. ##STR00001##

Novel substituted 5 membered heterocyclic compounds of Formula I are disclosed. The invention further discloses a process for the preparation of compounds of Formula I. The compounds find use as anti mycobacterial agents. ##STR00001##

The present invention relates to various organic reactions including a method for producing heterocyclic compounds using a [3+2] annulation; a method for producing fluorinated heteroaromatic compounds; and a method for alkylating a meta-position of a phenolic compound.

The present invention relates to various organic reactions including a method for producing heterocyclic compounds using a [3+2] annulation; a method for producing fluorinated heteroaromatic compounds; and a method for alkylating a meta-position of a phenolic compound.

The present invention relates to a compound having the following formula (I): wherein:—A is a (hetero)aryl radical comprising from 5 to 10 carbon atoms, possibly substituted by at least one substituent chosen from the group consisting of: halogen atoms, amino, azido, cyano, nitro, hydroxyl, formyl, carboxyl, amido, (C.sub.1-C.sub.6)alkyl groups, halo(C.sub.1-C.sub.6)alkyl groups, (C.sub.1-C.sub.6)alkoxy groups, alkenyl groups, cycloalkenyl groups, and alkynyl groups, and—R is H, CN or CF.sub.3, or their pharmaceutically acceptable salts, racemates, diastereomers or enantiomers.

##STR00001##